AstraZeneca
To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.
Breast Cancer
The objectives of this study are to assess the safety and effectiveness of Capivasertib (hereinafter "the study drug") in a real-world practice setting for patients prescribed with the study drug under the approved local label in South Korea. Primary Objective To assess the safety of the study drug in patients prescribed with the study drug under the approved label(s) in South Korea Secondary Objective To assess effectiveness of the study drug in patients prescribed with the study drug under the approved label(s) in South Korea
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 130 participants |
| Official Title : | CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA |
| Actual Study Start Date : | 2025-12-31 |
| Estimated Primary Completion Date : | 2030-02-28 |
| Estimated Study Completion Date : | 2030-02-28 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 19 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
No Location Found